Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Navidea Biopharmaceuticals Inc
(NY:
NAVB
)
N/A
UNCHANGED
Last Price
Updated: 8:00 PM EDT, Oct 5, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Navidea Biopharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV
July 25, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
July 20, 2022
From
Navidea Biopharmaceuticals, Inc
Via
Business Wire
Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding
July 05, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
May 24, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting
May 23, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results
May 12, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update
May 05, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea's Imaging Agent Can Distinguish Between Fibroid & Non-Fibroid Pathotype Of Rheumatoid Arthritis
April 20, 2022
Via
Benzinga
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
April 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
April 20, 2022
Another day of trading is waiting for investors and we're kicking it off with a look at the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis
April 20, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets
April 20, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
21 Stocks Moving in Wednesday's Pre-Market Session
April 20, 2022
Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) rose 24.1% to $1.80 in pre-market trading after jumping around 22% on Tuesday. ToughBuilt Industries, Inc. (NASDAQ:...
Via
Benzinga
54 Biggest Movers From Yesterday
April 20, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to...
Via
Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
April 19, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to acquire the company for $...
Via
Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
April 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 19, 2022
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis
April 19, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
23 Stocks Moving in Tuesday's Pre-Market Session
April 19, 2022
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS...
Via
Benzinga
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India
April 18, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series
April 12, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
April 12, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs
April 07, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
March 29, 2022
Good morning! It's time to start another busy day of trading with another breakdown of the biggest pre-market stock movers on Tuesday!
Via
InvestorPlace
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
March 23, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Recap: Navidea Biopharmaceutical Q4 Earnings
March 23, 2022
Navidea Biopharmaceutical (AMEX:NAVB) reported its Q4 earnings results on Wednesday, March 23, 2022 at 07:30 AM. Here's what investors need to know about the...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
March 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
March 23, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For March 23, 2022
March 23, 2022
Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter. • First Trust NASDAQ Clean Edge Smart Grid...
Via
Benzinga
Earnings Outlook For Navidea Biopharmaceutical
March 22, 2022
Navidea Biopharmaceutical (AMEX:NAVB) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement....
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.